Could cause temporary or reversible harm; serious harm is unlikely.
cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.
| Brand name | CLOMIPRAMINE HYDROCHLORIDE |
| Generic name | CLOMIPRAMINE HYDROCHLORIDE |
| Active ingredient(s) | CLOMIPRAMINE HYDROCHLORIDE |
| Distributed by / for | Northstar Rx LLC, Memphis, TN 38141 |
| NDC | 16714-849-01 |
| Full product label | clomiPRAMINE Hydrochloride, Capsules, USP, 25 mg, packaged in a) 30-count bottles (NDC 16714-849-01), b) 90-count bottles (NDC 16714-849-02), c) 100-count bottles (NDC 16714-849-03), Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India |
| Recalling firm | Zydus Pharmaceuticals (USA) Inc |
| Distribution | Nationwide in the US |
| Quantity | N/A |
| Recall initiated | 2025-10-22 |
| Report date | 2025-11-12 |
| Recall completed | — |
| Recall number | D-0152-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Pennington NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗